Search Results
Apr 28, 2026, 03:41 ET Breaking Physical Limits to Reshape Future Mobility: Dreame Nebula NEXT Debuts Rocket-Powered Concept Car "Jet Edition" in U.S.
the foundational level, this system integrates the vehicle's cockpit, driving functions, and chassis. When paired with the company's automotive LiDAR-DHX1 -- which has been co-developed and customized in collaboration with our core partner -- it aims to eliminate driving blind-spots in extreme weather
More news about: Dreame Nebula NEXT
Apr 27, 2026, 20:09 ET Dreame Launches Nebula NEXT 01 JET Edition at DREAME NEXT: Dual E-engine and Rocket-Powered Intelligent Vehicle with 0.9-Second 0-100 km/h Sprint
150 milliseconds, generates a peak thrust of 100 kN, and delivers a 0-to-100 km/h time of 0.9 seconds. Alongside the vehicle, Dreame introduced the DHX1, the first LiDAR unit developed under the Nebula Next program with partners. In high-performance mode, a leap that Dreame describes as moving automotive
More news about: Dreame Technology
Oct 22, 2025, 12:00 ET Accent Therapeutics Presents New Preclinical Data on Lead Clinical Programs ATX-295 and ATX-559 at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
ATX-559 (DHX9 Inhibitor) Title: ATX-559, a First-in-Class, Clinical-Stage DHX9 Inhibitor, as a Targeted Therapeutic for Molecularly Defined
More news about: Accent Therapeutics
Oct 08, 2025, 08:00 ET Boehringer Ingelheim Obtains Novel Preclinical Oncology Program from Accent Therapeutics
populations with significant unmet need. The company's two lead programs—ATX-559, targeting DHX9, and ATX-295, targeting KIF18A—are currently being evaluated in Phase 1/2 clinical studies. ATX-559 is a first-in-class DHX9 inhibitor targeting tumors with high replication stress (e.g., BRCA, MSI-H/dMMR)
More news about: Accent Therapeutics